Glioma cell (null)

Glioma cells are the neoplastic cells that form gliomas, representing approximately 30% of primary brain tumors and the majority of brain tumor-related deaths, with subtypes including astrocytomas, oligodendrogliomas, and glioblastomas classified by the 2021 WHO system based on molecular markers like IDH mutations, 1p/19q codeletion, TP53 mutations, ATRX loss, CDKN2A/B deletion, EGFR amplification, and TERT promoter mutations. These cells originate from neuroglial stem cells and exhibit hallmarks of cancer such as uncontrolled proliferation, invasion into surrounding brain tissue, resistance to apoptosis, and genomic instability driven by these alterations. For instance, IDH-mutant astrocytoma cells often co-occur with TP53 and ATRX mutations promoting an astrocytic phenotype, while oligodendroglial cells feature 1p/19q codeletion and TERT mutations. Glioblastoma cells, typically IDH-wildtype, show EGFR amplification, chromosome 7 gain/+10 loss, enabling aggressive growth and poor prognosis. No specific drugs directly target "glioma cells" as a receptor or enzyme; therapies like temozolomide or bevacizumab address tumor-associated pathways, but glioma cells' heterogeneity and blood-brain barrier limit efficacy. This cellular entity is not druggable as a single molecular target, serving instead as the pathological focus for glioma classification and prognosis.

Other names

Diffuse glioma cellAstrocytoma cellOligodendroglioma cellGlioblastoma cell (GBM cell)

null